Activity Survey 2014

Patient and Transplant Numbers

Teams: 656  Participating countries: 47

<table>
<thead>
<tr>
<th></th>
<th>Allogeneic</th>
<th>Autologous</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st Allo/auto HSCT</td>
<td>15765</td>
<td>20704</td>
<td>36469</td>
</tr>
<tr>
<td>Retransplant</td>
<td>1105</td>
<td>1594</td>
<td>2699</td>
</tr>
<tr>
<td>Additional transplant</td>
<td>76</td>
<td>1585</td>
<td>1661</td>
</tr>
<tr>
<td>Total</td>
<td>16946</td>
<td>23883</td>
<td>40829</td>
</tr>
</tbody>
</table>

Main Indications 1st HSCT

**Leukaemia**
- AML 1st CR: 3670
- ALL 1st CR: 1537
- CML 1st CR: 198
- MDS or MPN: 2393
- CLL: 353

**Lymphoid neoplasia**
- B-cell disorders: 580
- Hodgkin lymphoma: 477
- Non-Hodgkin lymphoma: 1235

**Solid tumour**
- Neuroblastoma: 16
- Soft tissue sarcoma: 9
- Breast cancer: 5
- Ewing: 7
- Other solid tumour: 7

**Non-malignant disorder**
- Bone marrow failure - SAA: 617
- Bone marrow failure - other: 216
- Hemoglobinopathy-thalassemia: 337
- Hemoglobinopathy-sickle: 105
- Primary immune deficiency: 499
- Inherited disorder of metabolism: 155
- Auto immune disorder: 13
- Others: 139

HSCT in Europe 2014

Main Indication by transplant type

**Allogeneic**
- Hemoglobinopathy: 3%
- BM: 5%
- ST: 3%
- NHL: 8%
- HD: 3%
- PCO: 4%
- CML: 3%

**Autologous**
- AML: 36%
- NHL: 29.3%
- HD: 9.8%
- PCO: 50.3%

Numbers of HSCT and teams by donor type in Europe 1990 to 2014

*Absolute numbers of HSCT*

*Percentage increase in HSCT activity between the years 2004 and 2014 in countries reporting >100 HSCT in 2014*

Increase in allogeneic HSCT

Increase in autologous HSCT

Paediatric patients

**Family**

- HLA-identical twin
- HLA-identical sibling
- HLA-identical family
- Non-HLA-identical
- Unrelated
- Autologous

**Donor type**

- BM
- PBPC
- Cord

<table>
<thead>
<tr>
<th></th>
<th>HLA-identical twin</th>
<th>HLA-identical sibling</th>
<th>HLA-identical family</th>
<th>Non-HLA-identical</th>
<th>Unrelated</th>
<th>Autologous</th>
</tr>
</thead>
<tbody>
<tr>
<td>BM</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>PBPC</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>Cord</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
</tbody>
</table>

Additional information

- Non myeloablative transplants: 6871
- No. patients with DLI: 2649
- Celluar therapies
  - No. patients with MSC for GvHD treatment/prevention: 450
  - No. patients with MSC for graft enhancement: 27
  - No. patients with MSC unspecified: 48

helen.baldomero@usb.ch

www.ebmt.org

#EBMT16